Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01732614 · ClinicalTrials.gov registry record · NA
Topcon Endpoint Management
A NA study, sponsored by Retinal Consultants of Arizona.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT01732614 is a NA study that has completed, run by Retinal Consultants of Arizona. The registered enrollment target is 10 participants.
The verdict
NCT01732614, a NA study, has completed, sponsored by Retinal Consultants of Arizona.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
This trial seeks to prove that sub-lethal laser power levels are as effective and less damaging than traditional laser. Diabetic macular edema (DME) affects approximately 29% of diabetic patients with a disease duration of 20 or more years and is one of the most frequent causes of vision loss in this population. The Early Treatment Diabetic Retinopathy Study (ETDRS) demonstrated a significant benefit of laser photocoagulation for the treatment of clinically significant macular edema, reducing the incidence of vision loss by approximately 50% at 3 years' follow-up.
Interventions
- PROCEDURE Topcon Endpoint Management laser
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01732614
The ClinicalTrials.gov registry entry for NCT01732614 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Retinal Consultants of Arizona, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Topcon Endpoint Management laser is the first listed.
NCT01732614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01732614 about?
NCT01732614 is a clinical study titled "Topcon Endpoint Management". This trial seeks to prove that sub-lethal laser power levels are as effective and less damaging than traditional laser. Diabetic macular edema (DME) affects approximately 29% of diabetic patients with a disease duration of 20 or more years and is one of the most frequent causes of vision loss in thi...
What is the current status of trial NCT01732614?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2012-08. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01732614?
The interventions under investigation include: Topcon Endpoint Management laser (PROCEDURE).
Who is sponsoring clinical trial NCT01732614?
This trial is sponsored by Retinal Consultants of Arizona, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.